JP Morgan Private Wealth Advisors’s Myriad Genetics MYGN Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-14,584	Closed	-$418K	–	1490
2019 Q3	$418K	Buy	14,584 +4,947	+51%	+$144K	﹤0.01%	1057
2019 Q2	$268K	Sell	9,637 -159	-2%	-$4.49K	﹤0.01%	1190
2019 Q1	$325K	Buy	9,796 +1,326	+16%	+$40.4K	﹤0.01%	1177
2018 Q4	$246K	Buy	+8,470	New	+$305K	﹤0.01%	1256
2017 Q3	–	Sell	-9,597	Closed	-$248K	–	1266
2017 Q2	$248K	Sell	9,597 -5,839	-38%	-$124K	﹤0.01%	1084
2017 Q1	$296K	Buy	+15,436	New	+$274K	﹤0.01%	1073
2016 Q4	–	Sell	-11,322	Closed	-$233K	–	1278
2016 Q3	$233K	Buy	11,322 +484	+4%	+$12.3K	﹤0.01%	1087
2016 Q2	$331K	Buy	10,838 +55	+0.5%	+$1.91K	﹤0.01%	938
2016 Q1	$404K	Buy	10,783 +4,886	+83%	+$184K	﹤0.01%	820
2015 Q4	$255K	Buy	+5,897	New	+$249K	﹤0.01%	932

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JP Morgan Private Wealth Advisors's MYGN Position: Q4 2019 in Review

JP Morgan Private Wealth Advisors sold out of Myriad Genetics (MYGN) in Q4 2019, closing a stake of 14,584 shares — an estimated $418K sold.

JP Morgan Private Wealth Advisors first reported a position in MYGN in Q4 2015 and held it in 10 quarters. The position peaked at $418K in Q3 2019. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

JP Morgan Private Wealth Advisors reported no remaining Myriad Genetics position as of Q4 2019 after selling out during the quarter.
JP Morgan Private Wealth Advisors sold 14,584 Myriad Genetics shares in Q4 2019, an estimated $418K.
JP Morgan Private Wealth Advisors first reported a position in Myriad Genetics in Q4 2015 and held it in 10 quarters.
JP Morgan Private Wealth Advisors's Myriad Genetics position peaked at $418K in Q3 2019.
227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.